Kitex is generally considered relevant for symptomatic relief of acute pain, inflammation, and fever, in line with its approved therapeutic indications. This medicine is commonly used across therapeutic domains to address symptoms that interfere with daily functioning.

Acute Musculoskeletal and Trauma-Related Discomfort

This domain addresses symptoms related to physical discomfort arising from physical stress, such as symptoms associated with sprains, strains, and inflammation linked to musculoskeletal injuries. It is considered relevant in contexts where additional symptomatic support is needed. It provides supportive relief that generally helps ease the overall symptom load during periods of heightened discomfort.

Episodic and Cyclical Symptom Management

Kitex is commonly used across conditions characterized by episodic or fluctuating manifestations, such as symptoms associated with dysmenorrhoea, as well as acute discomfort following dental or medical procedures. It helps address symptom clusters that may become intense or disruptive, creating noticeable physiological strain. This application supports patients during difficult episodes by easing distress.

Quick Fact: Symptomatic support for Acute Discomfort The medicine is considered relevant when short-term symptomatic assistance is appropriate, supporting patients during episodes of heightened discomfort.

Regulatory References

1. Irish Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility Map: Who Can and Cannot Use Kitex

The eligibility for Kitex (Dexketoprofen) is strictly governed by patient characteristics detailed in official regulatory labeling. Use is primarily approved for adults (18 years and older) who do not have any contraindications.

---

Eligibility Classification	Prohibited or Restricted Populations
Absolute Contraindication	Patients with a history of peptic ulcer/GI bleeding, severe heart failure, moderate-to-severe renal impairment (creatinine clearance leq 59 ml/min), or severe hepatic impairment (Child-Pugh 10 -15).
	Patients with Crohn's disease, ulcerative colitis, or active bleeding disorders.
	Individuals with a known hypersensitivity to any NSAID, including aspirin, or those who experience asthma/angioedema from NSAID use.
Age Restriction	Children and Adolescents (under 18 years) are not recommended for use, as safety and efficacy are not established in this age group.
Pregnancy/Lactation	Contraindicated during the third trimester of pregnancy and during breastfeeding.
Conditional Use	Older adults and patients with mild renal or hepatic impairment require close monitoring and must begin treatment at the lowest initial dose available, as specified in regulatory documents.

---

These official eligibility rules establish specific non-eligible groups to minimize risk, defining those who must not use the medicine, such as patients with severe organ dysfunction. Populations with a higher baseline risk, including older adults, are categorized for conditional use, necessitating the lowest possible dose and close clinical observation.

Interactions with other medicines and products

Regulatory documents establish specific restrictions based on the interaction profile of Kitex (Dexketoprofen).

Property	Statement
Medicinal product categories with documented interactions	Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Oral Anticoagulants, Antiplatelet agents, Methotrexate, Lithium salts, Diuretics, and Selective Serotonin Reuptake Inhibitors (SSRIs).
Mechanistic basis of interactions	Pharmacodynamic (PD) Interaction: Enhanced risk of bleeding or ulceration; potential worsening of renal function. Pharmacokinetic (PK) Interaction: Reduced renal clearance of co-administered medicines, increasing their plasma concentration.
Timing-based interaction rules	Administration with food delays the absorption rate and reduces the peak concentration (C max); administration is recommended at least 30 minutes before meals in the treatment of acute pain.
Population-specific interaction notes	Elderly patients have an officially noted increased risk of adverse reactions resulting from interactions.

Interaction Classifications (High-Level)

Property	Statement
Interaction severity classification	Contraindicated: Co-administration with other NSAIDs, high-dose Methotrexate (ge 15 mg/ week), oral anticoagulants (e.g., Warfarin), and full-dose Heparin is prohibited.
Official interaction statements	Co-administration with Lithium carries a risk of increased plasma concentration. The risk of gastrointestinal bleeding is increased when co-administered with Corticosteroids or SSRIs. Mandatory monitoring of renal function is required when co-administered with Ciclosporin or Tacrolimus.

Mechanism of Action: Inhibition of Prostanoid Synthesis

The action of Dexketoprofen is defined by its function as a non-selective inhibitor of the Cyclooxygenase (COX) enzyme system. The active molecule blocks the activity of both the constitutive COX-1 and the inducible COX-2 enzymes, which are responsible for the conversion of arachidonic acid into prostanoids.

This inhibition results in the reduction of key lipid mediators, particularly Prostaglandin E2 ( PGE2), which plays a central role in inflammatory and thermal responses. Peripherally, the resulting low PGE2 levels reduce the excitability and sensitization of peripheral nociceptive fibers. Centrally, the mechanism extends to the hypothalamus, where the suppression of PGE2 production results in the biological resetting of the elevated temperature set-point, driving a thermoregulatory effect. This sequence of molecular and cellular events forms the basis for the drug's functional effect profile.

The official instructions for using Kitex define precise rules for administration, dosage, and frequency to ensure correct usage. The official administration guidelines must be followed strictly.

Official Administration Guidelines

Parameter	Official Instruction
Route of Administration	Oral (tablets, liquid, powders), Rectal (suppositories), and Intravenous (IV) Infusion.
Standard Dosing	Adults (ge 50 kg): 650 mg to 1,000 mg per single dose. The maximum total daily dose from all sources must not exceed 4,000 mg in 24 hours.
Frequency/Interval	A minimum interval of 4 hours must be observed between doses. Do not exceed 4 doses in any 24-hour period (for most oral products).
Age-Group Rules	Dosing for children and adolescents weighing less than 50 kg is strictly weight-based (10 to 15 mg/kg per dose). Consult the product label for specific age- and weight-based pediatric dosing charts.
Preparation Requirements	Oral suspensions must be shaken well before each use. Effervescent tablets must be fully dissolved in water before ingestion. Use the manufacturer’s dosing device (syringe or cup) to measure liquid doses accurately.
Missed Dose Rule	If a regular dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not take a double dose.

These instructions collectively define the mandated procedural structure for using the medicine. The official protocol is centered on preventing accidental overdose by strictly adhering to the minimum time interval and the absolute maximum daily limit, irrespective of the administration route used.

Research Evidence / Overview of Studies for Kitex

The following overview summarizes the clinical evaluation of Kitex (Dexketoprofen trometamol), drawing exclusively from official regulatory documents, randomized controlled trials, and high-quality peer-reviewed scientific literature.

---

Evidence for Use in Acute Postoperative Pain

Research has primarily involved short-term, randomized controlled trials (RCTs) conducted in adult populations experiencing phases of heightened symptom activity following standardized surgical procedures, such as dental or orthopedic surgery. In these trials, researchers primarily measured the Time to the measured reduction in perceived discomfort and the overall change in pain measurements over a few hours.

The findings describe patterns observed in the studies in relation to acute changes. Some trials monitored the time required for the pattern of change related to measured discomfort to be observed following single-dose administration, and also monitored the time until patients requested supplementary pain medication. However, the existing evidence is highly concentrated on short-term, single-dose effects; long-term effects are not fully established, and there is limited information for outcomes beyond the immediate post-operative period.

---

Evidence for Use in Acute Musculoskeletal and Trauma-Related Discomfort

Research has explored the use of Kitex in conditions associated with acute or disruptive episodes, such as acute low back pain or soft tissue injuries. The core evidence is derived mainly from randomized controlled trials (RCTs) which included placebo and active comparators over periods typically lasting up to two weeks. The outcomes related to physical discomfort were evaluated using scales where patients reported their perceived discomfort, and studies monitored changes in measured pain intensity and outcomes reflecting daily functioning.

These trials focused on the acute phase. Long-term effects are not fully established, and research provides limited insight into sustained functional improvement over extended periods.

---

Research Gaps and Areas of Uncertainty

The evidence base for Kitex, while substantial for acute pain models, has several areas of uncertainty. The follow-up durations were limited across the majority of key studies, meaning research has explored only short-term changes. Data for certain groups remain insufficient; for instance, there is limited information for the use of Kitex in pediatric populations or older adults with comorbidities. The research highlights what is known about patterns related to the timing of change in measured discomfort, but the research does not determine whether an individual will respond similarly.

Key Studies & References Irish Health Products Regulatory Authority (HPRA) Summary of Product Characteristics: Kitex (Dexketoprofen Trometamol)

Common questions about Kitex (FAQ)

Q: Does Kitex cause drowsiness or fatigue?

According to the official product information, drowsiness (somnolence) and fatigue are listed as possible side effects. If these effects are experienced, it is consistent with official warnings to avoid activities requiring high alertness, such as driving or operating machinery.

Q: Is it common for people to experience changes in mood while on Kitex?

Mood disturbances are listed in regulatory documents as a very rare side effect of this medicine. Any changes in mood or emotional state experienced while taking Kitex are advised to be discussed with a healthcare professional.

Q: Can Kitex be taken by people who are sensitive to certain dyes or fillers?

Official product documentation lists all inactive ingredients, also known as excipients, used in the different formulations of the medicine. The complete list of excipients may be reviewed with a pharmacist to identify any known sensitivities before use.

Q: Is Kitex safe to take if I have high blood pressure?

Regulatory documents advise that caution and close monitoring are required for patients who have hypertension (high blood pressure) or a history of heart failure when considering NSAID treatment. Discussion of these conditions with a doctor or pharmacist is necessary, as official guidance requires special consideration before initiating treatment.

Q: Are there any known interactions with alcohol consumption while on Kitex?

Official warnings advise against alcohol consumption during treatment with Kitex. Drinking alcohol may increase the risk of certain side effects, such as drowsiness and complications related to the stomach and digestive tract, including gastrointestinal bleeding.

Q: Is Kitex habit-forming or does it carry a risk of dependence?

The regulatory documents for the active ingredient in Kitex, Dexketoprofen, do not report habit-forming tendencies or a risk of dependence. This information is typically confirmed by major regulatory agencies like the FDA and EMA.

Q: What information is provided about Kitex in the patient leaflet?

The Patient Information Leaflet (PIL) is a mandatory document that accompanies the medicine, providing essential patient-friendly details. It contains information on the medicine’s purpose, proper use, storage, potential warnings, possible side effects, and known drug interactions, as required by health authorities.

Q: Is Kitex suitable for people with diabetes?

Patients with diabetes are considered to have a cardiovascular risk factor that requires consideration when using NSAIDs. Discussion of the treatment plan with a doctor or pharmacist is recommended for proper risk assessment, as these conditions are factors that require clinical consideration.

Q: Does Kitex typically cause weight gain or loss?

Official side effect reports list fluid retention and edema (swelling) as potential adverse reactions associated with NSAIDs like Kitex. While not the same as weight gain, this fluid retention may contribute to temporary weight changes in some users.

Q: Are the side effects of Kitex the same for everyone?

No, the official list of side effects in regulatory documents categorizes events by how often they occur, such as common, uncommon, or rare. This classification indicates that the experience of side effects varies significantly among users.

Q: Is it true that Kitex helps improve [general expectation, e.g., energy levels]?

The medicine is officially recognized for its analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) effects. There is no official information stating that the medicine is indicated for or helps to improve general factors such as energy levels.

Q: Does Kitex require a special diet?

No special diet is required by regulatory documents for use with Kitex. However, for maximum effectiveness in treating acute pain, the official administration guidelines advise taking the medicine at least 30 minutes before meals.

Q: Is there a specific time of day Kitex is recommended to be taken?

There is no specific time of day (e.g., morning or evening) mandated for taking Kitex. The most critical instruction is to follow the minimum time interval (such as 4-8 hours) between doses and not exceed the maximum daily limit, as specified in regulatory documents.

Storage Conditions

Kitex (Dexketoprofen trometamol) must be stored out of the reach of children.

Required storage conditions vary by formulation and packaging:

• Tablets must be stored at a cool and dry place, requiring protection from both light and moisture. Certain tablet packaging types must be kept in the outer carton and stored below 30 C.
• Injection/Infusion ampoules must be kept in the outer carton to protect the solution from light. Once the solution is diluted for infusion, it must be protected from natural daylight during administration.
• The granules for oral solution and the diluted injectable solution must be used immediately after preparation or removal from the ampoule.

Disposal Instructions

Any unused or expired medicinal product or waste material must be disposed of in accordance with local regulatory requirements.